

2nd International Baltic Symposium

Management of TB/HIV co-infected patients: challenges and opportunities to End TB Strategy

May 19-20, 2017

Radisson Blu Hotel Latvija, 55 Elizabetes street, Riga, Latvia

Background

The first International Baltic Symposium was organized in Riga in May 2016 to scale up the use of new drugs (ND) in safe and effective manner and improve treatment outcomes for multidrug-resistant, extensively drug resistant tuberculosis (M/XDR-TB) patients.

The second Baltic symposium is devoted to discuss, share experiences from countries, and to advocate at highest levels on using innovating technologies in diagnosis and treatment of dual M/XDR and Human immune deficiency virus (HIV) infection, including the use of ND for adults and children.

HIV associated TB and DR-TB remains a threat to public health despite the latest achievements. The burden of TB and HIV in the European Union and European Economic Area (EU/EEA) remains high - in 2014 about 30000 new HIV infections and 58000 TB cases were reported.

World Health Organization (WHO) strongly recommends implementation of testing of TB patients for HIV co-infection and exclusion of TB infection and/or disease in HIV-positive patients. The degree of implementation of this recommendation in the EU/EEA is unknown. TB patients HIV+ should be provided with combined antiretroviral therapy (ART, which improves survival and quality of life. Testing and preventive TB treatment of HIV and acute immune deficiency syndrome (AIDS) patients reduces TB incidence in HIV positive and may also reduce TB incidence in the general population.

The WHO End TB Strategy and its Sustainable Development Goals (SDGs) for 2030 calls for a 90% reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030, compared with 2015. To achieve these goals collaborative activities should be accelerated around the globe including Baltic countries.

Symposium is organized by WHO Collaborating Centre (WHO CC) for Research and Training in Management of MDR-TB of Latvia, Centre for TB and Lung Disease of Riga East

University Hospital (REUH), Latvian Centre of Infectious Diseases of REUH, in collaboration with non-governmental organization (NGO) “Tuberculosis Foundation of Latvia”, Tartu University Hospital, Estonian Society for Infectious Diseases, Hospital of Lithuanian University of Health Sciences, Vilnius University Hospital Santariskiu Klinikos, with support of Johnson & Johnson and Otsuka.

Goal

To introduce latest developments in management of TB/HIV co-infected patients.

Expected outcome

Country specific list of priority actions for adaptation of latest developments in management of TB/HIV co-infected patients.

Outline

TB/HIV epidemiology;

Latent TB infection (LTBI) diagnosis;

Laboratory diagnostics in TB/HIV co-infected patients;

Integrated care for all people affected by TB and HIV;

Updates on TB/HIV treatment;

TB/HIV management in children;

Efficacy and safety of new TB drugs in children;

Role of pharmacovigilance (PV) in National Public Health Programmes.

Duration

One and half day symposium (arrival on Friday, May 19; departure on Sunday, 20 of May).

Day I, 19.05.2017.		
Time	Session	Facilitator
11:00-12:00	Registration of participants and morning coffee	
Session I 12:00-13:00 Introduction Chairs: Dr. Andra Cirule, Prof. Matti Maimets		
12:00-12:20	Welcome. Opening	<i>Ministry of Health representatives from countries</i>
12:20-12:30	Goal and expected outcome	<i>Dr. Andra Cirule</i>
12:30-13:00	Country updates - management of TB/HIV co-infected patients: progress and challenges (10 minutes per country) 1. Estonia 2. Lithuania 3. Latvia	<i>Dr. Manfreds Danilovits Prof. Matti Maimets Prof. Skaidrius Miliauskas Prof. Raimonda Matulionyte Dr. Liga Kuksa Dr. Inga Azina</i>
<i>13:00-14:00 Lunch</i>		
Session II 14:00-16:00 Key Note Speakers Chairs: Prof. Skaidrius Miliauskas, Prof. Gunta Sture		
14:00-14:30	Integrated care for all people affected by tuberculosis (TB) and human immunodeficiency virus (HIV)	<i>Prof. Gunta Sture</i>
14:30-15:00	Latent TB infection (LTBI) in the immunocompromised patient: diagnosis and treatment.	<i>To be confirmed</i>
15:00-16:00	Present and future of laboratory diagnostics in TB/HIV co-infected patients. – 45 min present --15 min Q/A	<i>Dr. Daniela Maria Cirillo</i>
<i>16:00 – 16:30 Coffee Break</i>		
Session III 16:30-18:00 Challenges and opportunities in TB/HIV co- management “Two diseases, one patient” Chairs: Dr. Manfred Danilovits, prof. Raimonda Matulionyte		
16:30-17:00	TB/DR-TB/HIV patient management from TB specialist’s perspective	<i>Dr. Liga Kuksa</i>
17:00-17:30	TB/MDR-TB/HIV patient co-management from HIV specialist’s perspective	<i>Prof. Matti Maimets</i>
19:30	Dinner at Restaurant “Andaluzijas Suns”, 83 Elizabetes stret, Riga	

Day II, 20.05.2017.		
Time	Session	Facilitator
Session IV 9:00-11:30 Updates on treatment of DR-TB and HIV patients Chairs Dr. Liga Kuksa, Prof. Matti Maimets		
9:00-09:30	Updates on introduction of new and repurposed drugs for the treatment of drug resistant TB (DR-TB) patients.	Dr. <i>Gunta Dravniece</i>
9:30-10:00	Q&A	
<i>10:00-10:30 Coffee break</i>		
10:30-11:15	TB/HIV management in children. Efficacy and safety of new TB drugs in children + Q&A (15min)	<i>Prof. Iveta Ozere</i>
11:15-12:00	Role of pharmacovigilance in National Public Health Programmes. Causality assessment- why, how, what	<i>Linda Halmark</i>
12:00-13:00	Expert panel and Q&A	<i>Linda Halmark, Prof. Iveta Ozere, Dr Gunta Dravniece</i>
<i>13:00-14:00 Lunch</i>		
Session V 14:00-16:00 Way forward		
14:00-15:00	Discussions per country Gaps Priorities Actions	<i>Moderators Prof. Matti Maimets, Dr. Manfred Danilovits, Prof. Iveta Ozere, Prof. Gunta Sture, Prof. Skaidrius Miliauskas, Prof. Raimonda Matulionyte,</i>
15:00-16:00	Country presentations	<i>Dr. Gunta Dravniece, Prof. Matti Maimets</i>
16:00-16:30	Closing of Symposium Coffee and Departure	<i>Key country representatives Sponsors</i>

List of speakers in alphabetic order

Name	Institution	Country
Dr. Azina Inga	Latvian Centre of Infectious Diseases of Riga East University hospital	Latvia
Prof. Cirillo Daniela Maria	WHO Collaborating Centre, Supranational Reference Laboratory for MDR-TB control, San Raffaele Scientific Institute	Italy
Dr. Cirule Andra	Centre for TB and Lung Disease of Riga East University hospital	Latvia
Dr. Danilovits Manfred	Tartu University Hospital	Estonia
Dr. Dravniece Gunta	KNCV Tuberculosis Foundation	Netherlands
Harmark Linda	Netherlands Pharmacovigilance Centre Lareb	Netherlands
Dr. Kuksa Liga	WHO Collaborating Centre (WHO CC) for Research and Training in Management of MDR-TB of Latvia, Centre for TB and Lung Disease of Riga East University hospital	Latvia
Prof. Maimets Matti	Estonian Society for Infectious Diseases	Estonia
Prof. Matulionyte Raimonda	Vilnius University Hospital Santariskiu Klinikos	Lithuania
Prof. Miliauskas Skaidrius	Hospital of Lithuanian University of Health Sciences	Lithuania
Prof. Ozere Iveta	Riga Stradin`s University	Latvia
Prof. Sture Gunta	Latvian Centre of Infectious Diseases of Riga East University hospital	Latvia